Raymond James upgrades Chain Bridge Bancorp stock rating on rate outlook

Raymond James has reaffirmed its Strong Buy rating and set a $50.00 price target for Tyra Biosciences (NASDAQ:TYRA) shares, following a fireside chat with the company's CEO. The current stock price stands at $20.93, with analysts' targets ranging from $29 to $59, though InvestingPro analysis suggests potential overvaluation. Tyra recently presented initial Phase 2 data for its lead asset, dabogratinib, in non-muscle invasive bladder cancer, highlighting a strong dose response, 100% overall response rate, and safe chronic dosing.

This success could enable a future Phase 3 adjuvant study on disease-free survival following full bladder tumor removal, set to commence next year. Raymond James sees significant market potential for dabogratinib as the first oral therapy in this cancer type, with three opportunities generating a combined $2 billion revenue by 2035.

The firm models the company as financially robust, with more cash than debt and a current ratio of 14.91. Despite not yet being profitable, Tyra holds a solid cash position. Climb Bio was also added to Raymond James' Analyst Current Favorites list, with positive remarks about its drug pipeline, specifically derisked setup for CLYM116 and budoprutug.

Meanwhile, Tyra Biosciences encountered a price target reduction to $29 from H.C. Wainwright due to dilution from a recent capital raise, though the firm retained its Buy rating. Cantor Fitzgerald also reiterated its Overweight rating on Tyra Biosciences after reviewing Phase 2 SURF302 trial data for dabogratinib, which showed a 79% overall response rate and 64% complete response rate at a 60 mg once-daily dose.